Replies to post #144381 on Biotech Values

[iwfal]

Perhaps it is rare but this is where they should all be moving to, imo.

I agree on the 'should' - but I try not to underestimate human and organizational inertia -g-. E.g. sacrificing 1/2 or 3/4 of "your market" is probably a hard decision to make in big pharma. That said, I think there is a reasonable chance that future MET inhibitors will quickly move to using MET markers. But will MEK inhibitors use related markers? RAF inhibitors? ... . I suspect not.